- Report
- March 2025
- 391 Pages
Global
From €4232EUR$4,799USD£3,664GBP
- Report
- August 2025
- 188 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- September 2025
- 104 Pages
Global
From €5159EUR$5,850USD£4,466GBP
- Report
- February 2025
- 180 Pages
Global
From €3969EUR$4,500USD£3,436GBP
- Report
- May 2025
- 220 Pages
Global
From €4405EUR$4,995USD£3,814GBP
- Report
- February 2025
- 138 Pages
Global
From €2000EUR$2,429USD£1,792GBP
- Report
- March 2025
- 1000 Pages
Global
From €3440EUR$3,900USD£2,978GBP
- Report
- August 2025
- 182 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 190 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- August 2025
- 191 Pages
Global
From €3127EUR$3,545USD£2,707GBP
€3474EUR$3,939USD£3,007GBP
- Report
- September 2025
- 382 Pages
Global
From €5159EUR$5,850USD£4,466GBP
- Report
- June 2025
- 190 Pages
Global
From €3969EUR$4,500USD£3,436GBP
- Report
- January 2025
- 120 Pages
Global
€4990EUR$6,061USD£4,471GBP
- Report
- November 2024
- 525 Pages
Global
From €4232EUR$4,799USD£3,664GBP
- Report
- January 2025
- 363 Pages
Global
From €4232EUR$4,799USD£3,664GBP
- Report
- November 2024
- 799 Pages
Global
From €4232EUR$4,799USD£3,664GBP
- Report
- March 2025
- 1048 Pages
Global
From €4232EUR$4,799USD£3,664GBP
- Report
- March 2025
- 150 Pages
Global
From €2646EUR$3,000USD£2,290GBP
- Report
- November 2024
- 240 Pages
Global
From €2117EUR$2,400USD£1,832GBP
- Report
- August 2025
- 1300 Pages
Global
From €3704EUR$4,200USD£3,207GBP

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases.
Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments.
The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more